



1623

Patent Application
Attorney Docket No. 16234A

100 CENTER 1600/2900

MAR 20 2002

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 7th day of MARCH, 2002.

By

[Signature] 03/07/02
(Signature of person mailing)
RAYMOND M. SPEER, REG. NO. 26,810

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **MANTELL, ET AL.** :

APPLICATION NO.: **09/590,585** : Examiner:--

FILING DATE: **JUNE 8, 2000** : Group Art Unit: --

TITLE: **PURINE DERIVATIVES** :

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

[Signature]

RAYMOND M. SPEER
Attorney for Applicants
Reg. No. 26,810

Date: March 7, 2002

Pfizer Inc
Patent Department, 150-5-49
235 East 42nd Street
New York, NY 10017-5755
(212) 733-4606

#5
Jeda
3/23/02